ArticleCancer research2021
Activation of
Open access · bronzeAbstract read
In one paragraph
Article in Cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 21 citations in OpenAlex.
- Mutant ribosomal protein RPS15 drives B cell malignancy through oxidative stress and genomic instability.Nature communications · 2026Article
- CLL to Richter syndrome: Integrating network strategies with experiments elucidating disease drivers and personalized therapies.Science advances · 2025Article
- Overexpression of lncRNA TINCR inhibits cutaneous squamous cell carcinoma cells through promotes methylation of Myc and TERC genes.Archives of dermatological research · 2025Article
- A CADASIL NOTCH3 mutation leads to clonal hematopoiesis and expansion of Dnmt3a-R878H hematopoietic clones.Leukemia · 2025Article
- Tissue-specific roles of de novo DNA methyltransferases.Epigenetics & chromatin · 2025Review
- Review
- Notch signaling pathway in cancer: from mechanistic insights to targeted therapies.Signal transduction and targeted therapy · 2024Review
- Advances in epigenetic alterations of chronic lymphocytic leukemia: from pathogenesis to treatment.Clinical and experimental medicine · 2024Review
- Pancreatic Neuroendocrine Tumors: Signaling Pathways and Epigenetic Regulation.International journal of molecular sciences · 2024Review
- ZNF683 marks a CD8Cancer cell · 2023Article
- Clonal haematopoiesis and dysregulation of the immune system.Nature reviews. Immunology · 2023Review
- Review
- Old and New Facts and Speculations on the Role of the B Cell Receptor in the Origin of Chronic Lymphocytic Leukemia.International journal of molecular sciences · 2022Review
- Multiple Mechanisms of NOTCH1 Activation in Chronic Lymphocytic Leukemia: NOTCH1 Mutations and Beyond.Cancers · 2022Review
- Case report: Chronic lymphocytic leukemia/small lymphocytic lymphoma and monomorphic epitheliotropic intestinal T-cell lymphoma: A composite lymphoma.Pathology oncology research : POR · 2022Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors at 9 institutions in 2 countries.
Anat Biran *Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Shanye Yin *Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Helene KretzmerDepartment of Genome Regulation, Max Planck Institute for Molecular Genetics, Berlin, Germany.
Elisa Ten HackenDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Salma ParvinDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Fabienne LucasDepartment of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-4388-0349
Mohamed UdumanCenter for Immuno-Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-9725-0705
Catherine GutierrezDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0001-7453-2577
Nathan DangleDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Leah BillingtonDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Fara Faye RegisDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Laura Z RassentiMoores Cancer Center, University of California San Diego Health, La Jolla, California.
Arman MohammadBroad Institute of MIT and Harvard, Cambridge, Massachusetts.
Gabriela Brunsting HoffmannDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Kristen StevensonDepartment of Data Science, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Mei ZhengDepartment of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Elizabeth WittenDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Stacey M FernandesDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Eugen TauschDepartment of Internal Medicine III, Ulm University, Ulm, Germany.
Clare SunHematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.ORCID 0000-0001-8498-4729
Stephan StilgenbauerDepartment of Internal Medicine III, Ulm University, Ulm, Germany.
Jennifer R BrownDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Thomas J KippsMoores Cancer Center, University of California San Diego Health, La Jolla, California.ORCID 0000-0002-0064-4549
John C AsterDepartment of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Andreas GnirkeBroad Institute of MIT and Harvard, Cambridge, Massachusetts.ORCID 0000-0001-5324-6387
Donna S NeubergDepartment of Data Science, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0003-2566-3145
Anthony LetaiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0002-1993-9013
Lili WangDepartment of Systems Biology, Beckman Research Institute, City of Hope National Comprehensive Cancer Center, Monrovia, California.
Ruben D CarrascoHarvard Medical School, Boston, Massachusetts.
Alexander MeissnerDepartment of Genome Regulation, Max Planck Institute for Molecular Genetics, Berlin, Germany.
Catherine J WuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. cwu@partners.org.ORCID 0000-0002-3348-5054
Dana-Farber Cancer Institute · USHarvard University · USBrigham and Women's Hospital · USBroad Institute · USUC San Diego Health System · USUniversität Ulm · DECity of Hope · USMax Planck Institute for Molecular Genetics · DENational Heart Lung and Blood Institute · US
Funding
VectorP30CA006516 · NCI · DANA-FARBER CANCER INSTITUTE · PI Irene M. Ghobrial · 1985 to 2026
$330.6MTissue CoreP01CA081534 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KIPPS, THOMAS J · 2000 to 2016
$59.5MProteomicsP01CA206978 · NCI · DANA-FARBER CANCER INST · PI WU, CATHERINE JU-YING · 2016 to 2025
$17.0MITSC for Leukemia: Novel Molecular strategies for NCTN "Individualized" TherapiesUG1CA233338 · NCI · UNIVERSITY OF CINCINNATI · PI BYRD, JOHN C. · 2019 to 2025
$4.5M(PQ8) Genetically faithful murine models for studying disease progression in chronic lymphocytic leukemiaR01CA216273 · NCI · DANA-FARBER CANCER INST · PI WANG, LILI, WU, CATHERINE JU-YING · 2017 to 2021
$3.5MGenetic Predisposition to Chronic Lymphocytic Leukemia (CLL)R01CA258924 · NCI · DANA-FARBER CANCER INST · PI BROWN, JENNIFER R · 2021 to 2025
$3.1MUnlocking the Potential of PI3K Inhibition in CLLR01CA213442 · NCI · DANA-FARBER CANCER INST · PI BROWN, JENNIFER R · 2017 to 2021
$2.9MCooperation of SF3B1 mutations and ATM deletions in the pathogenesis of chronic lymphocytic leukemiaR01CA240910 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI WANG, LILI · 2020 to 2024
$2.1MNCI NIH HHS P01 CA081534NCI NIH HHS P01 CA206978NCI NIH HHS P30 CA006516NCI NIH HHS R01 CA213442NCI NIH HHS R01 CA216273NCI NIH HHS R01 CA240910NCI NIH HHS R01 CA258924NCI NIH HHS UG1 CA233338
Abstract
Chronic lymphocytic leukemia (CLL) is characterized by disordered DNA methylation, suggesting these epigenetic changes might play a critical role in disease onset and progression. The methyltransferase
Indexed as
Disease Models, AnimalDrug Resistance, NeoplasmAnimalsAnti-Bacterial AgentsApoptosisBiomarkers, TumorCell ProliferationDaptomycinDNA Methyltransferase 3AFemaleGene Expression Regulation, NeoplasticHumansLeukemia, Lymphocytic, Chronic, B-CellMaleMiceMice, Inbred NODAnti-Bacterial AgentsBiomarkers, TumorDaptomycinDNA Methyltransferase 3ADNMT3A protein, humanDnmt3a protein, mouseProto-Oncogene Proteins c-mycReceptors, Notch
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.